BCDA BioCardia

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025.

Dr. Altman will share recent business developments on the Company’s therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure.

Fireside Chat Details:

Date: Wednesday, May 21, 2025

Time: 03:40 p.m. EDT

Speaker: Peter Altman Ph.D., CEO

Moderator: Jim Molloy, AGP Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals

Webcast:

About BioCardia®

, headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit .



MEDIA CONTACT:
Miranda Peto, Investor Relations
 
(650) 226-0120

INVESTOR CONTACT:
David McClung, Chief Financial Officer
 
(650) 226-0120
EN
21/05/2025

Underlying

BCDABioCardia

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCardia

 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Announces New United States Patent for Helix Biotherapeutic ...

BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System SUNNYVALE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted US Patent No. 12,311,127 titled “Radial and Trans-endocardial Delivery Catheter”. US Patent No. 12,311,127 describes the Company’s minimally invasive interventional catheter systems to deliver biologic therapies to target sites in the he...

June 25, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare...

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025. Dr. Altman will sh...

May 21, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Reports First Quarter 2025 Business Highlights and Financial...

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s forma...

May 14, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia to Host Q1 2025 Corporate Update and Financial Results Confe...

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conferenc...

May 9, 2025 1 EN
 PRESS RELEASE
Free
BCDA BIOCARDIA

BioCardia Initiates Patient Enrollment at University of Wisconsin at M...

BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Elevated Markers of Cardiac Stress Dr. Amish Raval, Professor of Medicine at the University of Wisconsin School of Medicine and Public Health, to serve as Site Principal Investigator and Co-National Principal Investigator SUNNYVALE, Calif., May 06, 2025 (GLOBE NEWSWIRE) --   [Nasdaq: BCDA], a global leader in cellular...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch